Mamoglobina sérica como marcador predictor de recaída tumoral en cáncer de mama: revisión sistemática de la literatura

Abstract

Objective: To describe the effectiveness and usefulness of serum mammoglobin as a predictor of risk of tumor relapse in breast cancer through a systematic review of the literature.

Methodology: A systematic review of the literature was conducted. We searched the databases: Medline, Embase, Cochrane, Library and Scielo. A manual search was also performed through the references of the selected studies following and a search of gray literature in the databases of universities. Studies were selected in English and Spanish, not restricted by date.

Results: The initial electronic search yielded 180 references, at the end of which 8 studies were included in the review. Mammoglobin was found to be positive between 8 and 97% of participants before neoadjuvant treatment. In two studies, mammoglobin was associated with relapse free survival with HR: 2,840 (95% CI: 1.18-6.82) and 2.633 (95% CI: 1.25-5.54), three studies showed no relationship between mammoglobin and relapse HR: 05 (95% CI: 0.65-1.69), HR: 0.990 (95% CI: 0.10-9.80), HR: 0.989 (95% CI: 0.44-2.20) and one study showed relationship when Part of a scheme of three markers (mamoglobin / carcinoembronial antigen / CK19) HR: 12.4 (95% CI: 2.15-70.52).

Conclusions: The available literature on the evaluation of mammoglobin as a predictor of tumor relapse in breast cancer patients is scarce, with a high risk of bias and conflicting results. Further studies, with more methodological rigor, are required for a more homogeneous population that allow the determination of mammoglobin as an effective tumor marker as a predictor of tumor relapse.